Case Series of Responders to Sofosbuvir Plus Velpatasvir Based Combination Therapy for Hepatitis C in Chronic Kidney Disease Who are on Maintenance Hemodialysis
Case Series of Responders to Sofosbuvir Plus Velpatasvir Based Combination Therapy for Hepatitis C in Chronic Kidney Disease Who are on Maintenance Hemodialysis
Hepatitis C Virus (HCV) infection is a major infection worldwide, with 12.5 million people infected in India alone. In hemodialysis undergoing CKD population in specific, the prevalence of HCV is 4.3 – 45 %. It leads to accelerating decline of renal and liver functions causing higher mortality in hemodialysis patients. WHO recommends use of pan-genotypic, direct-acting anti-virals for the treatment of HCV. Sofosbuvir, in combination with other antivirals, led to a significant paradigm change in the treatment of HCV. Sofosbuvir is metabolized in the liver into an active metabolite which is not detected in circulation and an inactive metabolite that is excreted renally. Sofosbuvir and Velpatasvir combination of drugs was given to 10 HCV positive patients with CKD and on hemodialysis for 12 weeks. Viral load, after the completion of the treatment, were undetectable in all the patients. Sofosbuvir-Velpatasvir combination was demonstrated effective and safe in hemodialysis undergoing HCV patients.
Hepatitis C Virus (HCV) infection is a major infection worldwide, with 12.5 million people infected in India alone. In hemodialysis undergoing CKD population in specific, the prevalence of HCV is 4.3 – 45 %. It leads to accelerating decline of renal and liver functions causing higher mortality in hemodialysis patients. WHO recommends use of pan-genotypic, direct-acting anti-virals for the treatment of HCV. Sofosbuvir, in combination with other antivirals, led to a significant paradigm change in the treatment of HCV. Sofosbuvir is metabolized in the liver into an active metabolite which is not detected in circulation and an inactive metabolite that is excreted renally. Sofosbuvir and Velpatasvir combination of drugs was given to 10 HCV positive patients with CKD and on hemodialysis for 12 weeks. Viral load, after the completion of the treatment, were undetectable in all the patients. Sofosbuvir-Velpatasvir combination was demonstrated effective and safe in hemodialysis undergoing HCV patients.
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!